Cited by 5,198PARP inhibition in cancer therapyDNA Repair MechanismsBRCA gene mutations in cancer

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Open access

Bryant, Helen E., Schultz, Niklas, Thomas, Huw D., Parker, Kayan M., Flower, Dan, Lopez, Elena, Kyle, Suzanne, Meuth, Mark, Curtin, Nicola J., Helleday, Thomas·2005·Nature

DOI 10.1038/nature03443

Open this paper in CoChat — free account

Abstract

Poly(ADP-ribose) polymerase (PARP1) facilitates DNA repair by binding to DNA breaks and attracting DNA repair proteins to the site of damage. Nevertheless, PARP1-/- mice are viable, fertile and do not develop early onset tumours. Here, we show that PARP inhibitors trigger gamma-H2AX and RAD51 foci formation. We propose that, in the absence of PARP1, spontaneous single-strand breaks collapse replication forks and trigger homologous recombination for repair. Furthermore, we show that BRCA2-deficient cells, as a result of their deficiency in homologous recombination, are acutely sensitive to PARP inhibitors, presumably because resultant collapsed replication forks are no longer repaired. Thus, PARP1 activity is essential in homologous recombination-deficient BRCA2 mutant cells. We exploit this requirement in order to kill BRCA2-deficient tumours by PARP inhibition alone. Treatment with PARP inhibitors is likely to be highly tumour specific, because only the tumours (which are BRCA2-/-) in BRCA2+/- patients are defective in homologous recombination. The use of an inhibitor of a DNA repair enzyme alone to selectively kill a tumour, in the absence of an exogenous DNA-damaging agent, represents a new concept in cancer treatment.

Integrity signals

Registry

Crossref · 10.1038/nature03443

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Instability and decay of the primary structure of DNA
Lindahl, T. (1993) · Nature · doi:10.1038/362709a0 · Cited by 5,679
A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage
Paull, T. T., Rogakou, E. P., Yamazaki, V., Kirchgessner, C. U., Gellert, M., & Bonner, W. M. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00610-2 · Cited by 2,098
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
D’Amours, D., Desnoyers, S., D’Silva, I., & Poirier, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,819
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells
Murcia, J. M., Niedergang, C., Trucco, C., Ricoul, M., Dutrillaux, B., Mark, M. P., Oliver, F. J., Masson, M., Dierich, A., LeMeur, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7303 · Cited by 1,058
A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage
El‐Khamisy, S. F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg761 · Cited by 689
Functional interaction between PARP‐1 and PARP‐2 in chromosome stability and embryonic development in mouse
Murcia, J. M., Ricoul, M., Tartier, L., Niedergang, C., Huber, A., Dantzer, F., Schreiber, V., Amé, J., Dierich, A., LeMeur, M., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg206 · Cited by 629
Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks
Lindahl, T. L., Satoh, M. S., Poirier, G. G., & Klungland, A. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89089-1 · Cited by 611
PARP is important for genomic stability but dispensable in apoptosisPreprint
Wang, Z., Stingl, L., Morrison, C. G., Jantsch, M. F., Łoś, M., Schulze‐Osthoff, K., & Wagner, E. F. (1997) · Genes & Development · doi:10.1101/gad.11.18.2347 · Cited by 557

Flagged first, then by citations

Show all 26 references

Sorted by citations

Items 801–900 of 1,021

Targeted therapy for triple‐negative breast cancer: Where are we?
Duffy, M. J., McGowan, P. M., & Crown, J. P. (2012) · International Journal of Cancer · doi:10.1002/ijc.27632 · Cited by 105
Poly(ADP-ribosyl)ation in plants
Briggs, A. G., & Bent, A. F. (2011) · Trends in Plant Science · doi:10.1016/j.tplants.2011.03.008 · Cited by 105
FAM111A protects replication forks from protein obstacles via its trypsin-like domain
Kojima, Y., Machida, Y., Palani, S., Caulfield, T. R., Radisky, E. S., Kaufmann, S. H., & Machida, Y. (2020) · Nature Communications · doi:10.1038/s41467-020-15170-7 · Cited by 105
Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes
Wang, D., Li, C., Zhang, Y., Wang, M., Jiang, N., Lin, X., Li, T., Roberts, T. M., Zhao, J. J., Cheng, H.-L. M., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.07.092 · Cited by 105
Regulation of Recombination and Genomic MaintenancePreprint
Heyer, W. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016501 · Cited by 105
Olaparib
Bochum, S., Berger, S., & Martens, U. M. (2018) · Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_15 · Cited by 104
Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours
Conte, G. D., Sessa, C., von Moos, R., Viganò, L., Digena, T., Locatelli, A., Gallerani, E., Fasolo, A., Tessari, A., Cathomas, R. L., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.345 · Cited by 104
Synthetic lethal approaches to breast cancer therapy
Rehman, F. L., Lord, C. J., & Ashworth, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.172 · Cited by 104
MicroRNAs and DNA damage response
Wang, Y., & Taniguchi, T. (2012) · Cell Cycle · doi:10.4161/cc.23051 · Cited by 104
PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma
Colicchia, V., Petroni, M., Guarguaglini, G., Sardina, F., Roncero, M. S., Carbonari, M., Ricci, B., Heil, C., Capalbo, C., Belardinilli, F., et al. (2017) · Oncogene · doi:10.1038/onc.2017.40 · Cited by 104
PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data
Piñeiro-Yáñez, E., Reboiro‐Jato, M., Goméz-López, G., Perales-Patón, J., Troulé, K., Rodrı́guez, J. M., Tejero, H., Shimamura, T., Lopez-Casas, P. P., Carretero, J., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0546-1 · Cited by 104
The Tumor Suppressor PALB2: Inside Out
Ducy, M., Sesma-Sanz, L., Guitton-Sert, L., Lashgari, A., Gao, Y., Brahiti, N., Rodrigue, A., Margaillan, G., Caron, M., Côté, J., et al. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.10.008 · Cited by 104
Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy
Karanam, N. K., Ding, L., Asaithamby, A., & Story, M. D. (2019) · Translational research · doi:10.1016/j.trsl.2019.10.003 · Cited by 104
Uncoupling of PARP1 trapping and inhibition using selective PARP1 degradation
Wang, S., Han, L., Han, J., Li, P., Ding, Q., Zhang, Q.-J., Liu, Z., Chen, C., & Yu, Y. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0379-2 · Cited by 104
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
Xiong, Y., Guo, Y., Liu, Y., Wang, H., Gong, W., Liu, Y., Wang, X., Gao, Y., Yu, F., Su, D., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.06.009 · Cited by 104
PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCA
Risdon, E. N., Chau, C. H., Price, D. K., Sartor, O. A., & Figg, W. D. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0697 · Cited by 104
Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1
Ryan, K., Bolaños, B., Smith, M. L., Palde, P. B., Cuenca, P. D., VanArsdale, T. L., Niessen, S., Zhang, L., Behenna, D. C., Ornelas, M. A., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.016573 · Cited by 104
Radiation and New Molecular Agents Part I: Targeting ATM-ATR Checkpoints, DNA Repair, and the Proteasome
Choudhury, A., Cuddihy, A. R., & Bristow, R. G. (2005) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2005.08.007 · Cited by 104
Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
Kriege, M., Seynaeve, C., Meijers-Heijboer, H. E. J., Collee, M. J., Menke‐Pluymers, M. B. E., Bartels, C. C. M., Tilanus‐Linthorst, M. M. A., Blom, J., Huijskens, E., Jager, A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9067 · Cited by 104
Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature review
Hager, S., Ackermann, C. J., Joerger, M., Gillessen, S., & Omlin, A. G. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw156 · Cited by 104
Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation
Lesueur, P., Chevalier, F., El-Habr, E. A., Junier, M., Chneiweiss, H., Castéra, L., Müller, E., Stefan, D., & Saintigny, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-22022-4 · Cited by 104
Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM -Defective Tumors
Riabinska, A., Daheim, M., Herter-Sprie, G. S., Winkler, J., Fritz, C., Hallek, M. J., Thomas, R. K., Kreuzer, K., Frenzel, L. P., Monfared, P., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005814 · Cited by 103
New perspectives on targeted therapy in ovarian cancer
Coward, J. I. G., Middleton, K., & Murphy, F. (2015) · International Journal of Women s Health · doi:10.2147/ijwh.s52379 · Cited by 103
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal adenocarcinoma
O'Reilly, E. M., Lee, J. W., Lowery, M. A., Capanu, M., Stadler, Z. K., Moore, M. J., Dhani, N. C., Kindler, H. L., Estrella, H., Maynard, H., et al. (2018) · Cancer · doi:10.1002/cncr.31218 · Cited by 103
The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors
Miller, A. L., Fehling, S. C., Garcia, P. L., Gamblin, T. L., van Waardenburg, R. C. A. M., Yang, E. S.-H., Bradner, J. E., & Yoon, K. J. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.05.035 · Cited by 103
Synthetic Lethality of Wnt Pathway Activation and Asparaginase in Drug-Resistant Acute Leukemias
Hinze, L., Pfirrmann, M., Karim, S., Degar, J., McGuckin, C., Vinjamur, D. S., Sacher, J. R., Stevenson, K. E., Neuberg, D. S., Orellana, E. A., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.03.004 · Cited by 103
Targeting innate sensing in the tumor microenvironment to improve immunotherapy
Liu, Z., Han, C., & Fu, Y. (2019) · Cellular and Molecular Immunology · doi:10.1038/s41423-019-0341-y · Cited by 105
Poly(ADP-Ribose) Glycohydrolase (PARG) vs. Poly(ADP-Ribose) Polymerase (PARP) – Function in Genome Maintenance and Relevance of Inhibitors for Anti-cancer Therapy
Harrision, D., Gravells, P., Thompson, R. H., & Bryant, H. E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00191 · Cited by 103
Self-citation
Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps
Dias, M. P., Tripathi, V., van der Heijden, I., Cong, K., Manolika, E. M., Bhin, J., Gogola, E., Galanos, P., Annunziato, S., Lieftink, C., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.09.005 · Cited by 103
FBH1 Helicase Disrupts RAD51 Filaments in Vitro and Modulates Homologous Recombination in Mammalian Cells
Šimandlová, J., Zagelbaum, J., Payne, M., Chu, W. K., Shevelev, I., Hanada, K., Chatterjee, S., Reid, D. A., Liu, Y., Janščák, P., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.484493 · Cited by 103
Minding the gap: The underground functions of BRCA1 and BRCA2 at stalled replication forks
Nagaraju, G., & Scully, R. (2007) · DNA repair · doi:10.1016/j.dnarep.2007.02.020 · Cited by 103
Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents
Biddlestone-Thorpe, L., Marchi, N., Guo, K., Ghosh, C., Janigro, D., Valerie, K. C., & Yang, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.014 · Cited by 103
Targeting Abnormal DNA Repair in Therapy-Resistant Breast Cancers
Tobin, L. A., Robert, C., Nagaria, P. K., Chumsri, S., Twaddell, W. S., Ioffe, O. B., Greco, G. E., Brodie, A., Tomkinson, A. E., & Rassool, F. V. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-11-0255 · Cited by 103
Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors
Huang, F., Goyal, N., Sullivan, K., Hanamshet, K., Patel, M., Mazina, O. M., Wang, C. X., An, W. F., Spoonamore, J. E., Metkar, S. R., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw087 · Cited by 103
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
Knezevic, C. E., Wright, G. M., Rix, L. L. R., Kim, W., Kuenzi, B. M., Luo, Y., Watters, J. M., Koomen, J. M., Haura, E. B., Monteiro, Á. N. A., et al. (2016) · Cell chemical biology · doi:10.1016/j.chembiol.2016.10.011 · Cited by 103
Targeting DNA Replication Stress for Cancer Therapy
Zhang, J., Dai, Q., Park, D., & Deng, X. (2016) · Genes · doi:10.3390/genes7080051 · Cited by 102
Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias
Tobin, L. A., Robert, C., Rapoport, A. P., Gojo, I., Baer, M. R., Tomkinson, A. E., & Rassool, F. V. (2012) · Oncogene · doi:10.1038/onc.2012.203 · Cited by 102
Synthetic lethality: a framework for the development of wiser cancer therapeutics
Kaelin, W. G. (2009) · Genome Medicine · doi:10.1186/gm99 · Cited by 102
Serine-linked PARP1 auto-modification controls PARP inhibitor response
Prokhorova, E. A., Zobel, F., Smith, R., Zentout, S., Gibbs‐Seymour, I., Schützenhofer, K., Peters, A., Groslambert, J., Zorzini, V., Agnew, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24361-9 · Cited by 102
Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress
Bonagas, N., Gustafsson, N., Henriksson, M., Marttila, P., Gustafsson, R., Wiita, E., Borhade, S. R., Green, A. C., Vallin, K. S. A., Sarno, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00331-y · Cited by 104
Self-citation
DNA Damage Response Pathways in Tumor Suppression and Cancer Treatment
Liang, Y., Lin, S., Brunicardi, F. C., Goss, J. A., & Li, K. (2008) · World Journal of Surgery · doi:10.1007/s00268-008-9840-1 · Cited by 102
Rad17 recruits the MRE11‐RAD50‐NBS1 complex to regulate the cellular response to DNA double‐strand breaks
Wang, Q., Goldstein, M., Alexander, P. B., Wakeman, T. P., Sun, T., Feng, J., Lou, Z., Kastan, M. B., & Wang, X.-F. (2014) · The EMBO Journal · doi:10.1002/embj.201386064 · Cited by 102
Therapies for triple negative breast cancer
Andreopoulou, E., Schweber, S. J., Sparano, J. A., & McDaid, H. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032246 · Cited by 102
PARP Inhibitors for Cancer Therapy
Lin, K. Y., & Kraus, W. L. (2017) · Cell · doi:10.1016/j.cell.2017.03.034 · Cited by 101
Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
Ledermann, J. A., & Pujade-Lauraine, É. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919849753 · Cited by 101
Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer
Zhang, X., Yao, J., Li, X., Niu, N., Liu, Y., Hajek, R. A., Peng, G., Westin, S. N., Sood, A. K., & Liu, J. (2023) · Science Advances · doi:10.1126/sciadv.adf7195 · Cited by 101
Links between DNA double strand break repair and breast cancer: Accumulating evidence from both familial and nonfamilial cases
Ralhan, R., Kaur, J., Kreienberg, R., & Wiesmüller, L. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.06.004 · Cited by 101
The potential role and application of PARP inhibitors in cancer treatment
Chalmers, A. J. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldp005 · Cited by 101
Pathology of hereditary breast cancer
Silva, L. M. D., & Lakhani, S. R. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.37 · Cited by 101
DNA Polymerase θ: A Unique Multifunctional End-Joining Machine
Black, S., Kashkina, E., Kent, T., & Pomerantz, R. T. (2016) · Genes · doi:10.3390/genes7090067 · Cited by 101
Unravelling the genomic targets of small molecules using high-throughput sequencing
Rodriguez, R., & Miller, K. M. (2014) · Nature Reviews Genetics · doi:10.1038/nrg3796 · Cited by 100
Poly(ADP-ribosyl)ation in regulation of chromatin structure and the DNA damage response
Tallis, M., Morra, R., Barkauskaite, E., & Ahel, I. (2013) · Chromosoma · doi:10.1007/s00412-013-0442-9 · Cited by 100
Glioblastoma Cells Containing Mutations in the Cohesin Component STAG2 Are Sensitive to PARP Inhibition
Bailey, M. L., O’Neil, N. J., van Pel, D. M., Solomon, D. A., Waldman, T. A., & Hieter, P. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0749 · Cited by 100
Destabilization of linker histone H1.2 is essential for ATM activation and DNA damage repair
Li, Z., Li, Y., Tang, M., Peng, B., Lu, X., Yang, Q., Zhu, Q., Hou, T., Li, M., Liu, C., et al. (2018) · Cell Research · doi:10.1038/s41422-018-0048-0 · Cited by 100
DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation
Abbotts, R., Topper, M. J., Biondi, C., Fontaine, D., Goswami, R., Stojanovic, L., Choi, E. Y., McLaughlin, L. J., Kogan, A. A., Xia, L., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1903765116 · Cited by 100
FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination
Guo, E., Ishii, Y., Mueller, J., Srivatsan, A., Gahman, T. C., Putnam, C. D., Wang, J. Y. J., & Kolodner, R. D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009237117 · Cited by 100
Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies
Padella, A., di Rorà, A. G. L., Marconi, G., Ghetti, M., Martinelli, G., & Simonetti, G. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01228-0 · Cited by 100
DNA Damage and Its Role in Cancer Therapeutics
Moon, J., Kitty, I., Renata, K., Qin, S., Zhao, F., & Kim, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054741 · Cited by 100
Heat shock proteins as hallmarks of cancer: insights from molecular mechanisms to therapeutic strategies
Zuo, W., Pang, Q., Zhu, X., Yang, Q., Zhao, Q., He, G., Han, B., & Huang, W. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01601-1 · Cited by 108
Structural Basis for Inhibitor Specificity in Human Poly(ADP-ribose) Polymerase-3
Lehtiö, L., Jemth, A., Collins, R., Loseva, O., Johansson, A., Markova, N., Hammarström, M., Flores, A., Holmberg-Schiavone, L., Weigelt, J., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900052j · Cited by 100
Self-citation
PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells
Cheng, H., Zhang, Z., Borczuk, A., Powell, C. A., Balajee, A. S., Lieberman, H. B., & Halmos, B. (2013) · Carcinogenesis · doi:10.1093/carcin/bgs393 · Cited by 99
Coping with DNA double strand breaks
Hiom, K. J. (2010) · DNA repair · doi:10.1016/j.dnarep.2010.09.018 · Cited by 99
The role of poly(ADP-ribosyl)ation in DNA damage response and cancer chemotherapy
Li, M., & Yu, X. (2014) · Oncogene · doi:10.1038/onc.2014.295 · Cited by 99
The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity
Miknyoczki, S. J., Chang, H., Grobelny, J. V., Pritchard, S., Worrell, C. S., McGann, N., Ator, M. A., Husten, J., Deibold, J., Hudkins, R. L., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0062 · Cited by 99
BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance
Nacson, J., Krais, J. J., Bernhardy, A. J., Clausen, E., Feng, W., Wang, Y., Nicolas, É., Cai, K. Q., Tricarico, R., Hua, X., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.086 · Cited by 99
Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies
Molinaro, C., Martoriati, A., & Cailliau, K. (2021) · Cancers · doi:10.3390/cancers13153819 · Cited by 99
PARP inhibitors in metastatic prostate cancer
Taylor, A. K., Kosoff, D., Emamekhoo, H., Lang, J. M., & Kyriakopoulos, C. E. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1159557 · Cited by 99
Drug radiotherapy combinations: Review of previous failures and reasons for future optimism
Higgins, G. S., O'Cathail, S. M., Muschel, R. J., & McKenna, W. G. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.012 · Cited by 99
Targeting the Double-Strand DNA Break Repair Pathway as a Therapeutic Strategy
Lord, C. J., Garrett, M. D., & Ashworth, A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1269 · Cited by 99
DNA repair inhibition: a selective tumour targeting strategy
Madhusudan, S., & Hickson, I. D. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.09.004 · Cited by 99
Targeting DNA repair as a promising approach in cancer therapy
Damia, G. L. M., & D’Incalci, M. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.05.003 · Cited by 99
Poly (ADP-Ribose) Polymerase as a Novel Therapeutic Target in Cancer
Annunziata, C. M., & O’Shaughnessy, J. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0526 · Cited by 99
A novel small molecule RAD51 inactivator overcomes imatinib‐resistance in chronic myeloid leukaemia
Zhu, J., Zhou, L., Wu, G., Koenig, H., Lin, X., Li, G., Qiu, X., Chen, C., Hu, C., Goldblatt, E. M., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201760 · Cited by 99
Ubc13: the Lys63 ubiquitin chain building machine
Hodge, C. D., Spyracopoulos, L., & Glover, J. N. M. (2016) · Oncotarget · doi:10.18632/oncotarget.10948 · Cited by 99
DNA double-strand breaks: Their production, recognition, and repair in eukaryotes
Ohnishi, T., Mori, E., & Takahashi, A. (2009) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2009.06.010 · Cited by 98
Hyperthermia-induced DNA repair deficiency suggests novel therapeutic anti-cancer strategies
Eppink, B., Krawczyk, P. M., Stap, J., & Kanaar, R. (2012) · International Journal of Hyperthermia · doi:10.3109/02656736.2012.695427 · Cited by 98
Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide
Tentori, L., Ricci‐Vitiani, L., Muzi, A., Ciccarone, F., Pelacchi, F., Calabrese, R., Runci, D., Pallini, R., Caiafa, P., & Graziani, G. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-151 · Cited by 98
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1 - or BRCA2 -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083
Somlo, G., Frankel, P. H., Arun, B., Ma, C. X., García, A. A., Cigler, T., Cream, L., Harvey, H. A., Sparano, J. A., Nanda, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2714 · Cited by 98
Target engagement imaging of PARP inhibitors in small-cell lung cancer
Carney, B. D., Kossatz, S., Lok, B. H., Schneeberger, V. E., Gangangari, K. K., Pillarsetty, N., Weber, W., Rudin, C. M., Poirier, J. T., & Reiner, T. (2018) · Nature Communications · doi:10.1038/s41467-017-02096-w · Cited by 98
Co-Delivery of Doxorubicin and Anti-BCL-2 siRNA by pH-Responsive Polymeric Vector to Overcome Drug Resistance in In Vitro and In Vivo HepG2 Hepatoma Model
Sun, W., Chen, X., Xie, C. L., Wang, Y., Lin, L., Zhu, K., & Shuai, X. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00272 · Cited by 98
Distinct fibroblast functional states drive clinical outcomes in ovarian cancer and are regulated by TCF21
Hussain, A., Voisin, V., Poon, S., Karamboulas, C., Bui, N. H. B., Meens, J., Dmytryshyn, J., Ho, V. W., Tang, K. H., Paterson, J., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191094 · Cited by 98
Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy
Patterson-Fortin, J., & D’Andrea, A. D. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1672 · Cited by 98
Exploiting synthetic lethality to target BRCA1/2-deficient tumors: where we stand
Patel, P. S., Algouneh, A., & Hakem, R. (2021) · Oncogene · doi:10.1038/s41388-021-01744-2 · Cited by 98
BRCAness, DNA gaps, and gain and loss of PARP inhibitor–induced synthetic lethality
Li, X., & Zou, L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci181062 · Cited by 98
DNA Repair Pathway Gene Expression Score Correlates with Repair Proficiency and Tumor Sensitivity to Chemotherapy
Pitroda, S. P., Pashtan, I. M., Logan, H. L., Budke, B., Darga, T. E., Weichselbaum, R. R., & Connell, P. P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008291 · Cited by 98
Collaboration of Werner syndrome protein and BRCA1 in cellular responses to DNA interstrand cross-links
Cheng, W.-H., Kusumoto, R., Opresko, P. L., Sui, X., Huang, S., Nicolette, M. L., Paull, T. T., Campisi, J., Seidman, M. M., & Bohr, V. A. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl362 · Cited by 98
Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing
Evans, D. G., Lalloo, F. I., Cramer, A., Jones, E. A., Knox, F., Amir, E., & Howell, A. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2009.067850 · Cited by 98
A Radiotracer Strategy to Quantify PARP-1 Expression In Vivo Provides a Biomarker That Can Enable Patient Selection for PARP Inhibitor Therapy
Makvandi, M., Xu, K., Lieberman, B. P., Anderson, R., Effron, S. S., Winters, H. D., Zeng, C., McDonald, E. S., Pryma, D. A., Greenberg, R. A., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0416 · Cited by 98
Targeting poly(ADP-ribosyl)ation: a promising approach in cancer therapy
Haince, J.-F., Rouleau, M., Hendzel, M. J., Masson, J., & Poirier, G. G. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.08.003 · Cited by 98
ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition
Montani, M. S. G., Prodosmo, A., Stagni, V., Merli, D., Monteonofrio, L., Gatti, V., Gentileschi, M. P., Barilà, D., & Soddu, S. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-95 · Cited by 97
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
Gunderson, C. C., & Moore, K. N. (2015) · Future Oncology · doi:10.2217/fon.14.313 · Cited by 97
Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase
Gravells, P., Grant, E. K., Smith, K. M., James, D. I., & Bryant, H. E. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.02.010 · Cited by 97
Self-citation
Combating pancreatic cancer with PI3K pathway inhibitors in the era of personalised medicine
Conway, J. R. W., Herrmann, D., Evans, T. J., Morton, J. P., & Timpson, P. (2018) · Gut · doi:10.1136/gutjnl-2018-316822 · Cited by 97
Therapeutic Targeting of DNA Damage Response in Cancer
Choi, W., & Lee, E. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031701 · Cited by 97
Structure and repair of replication-coupled DNA breaks
Pavani, R., Tripathi, V., Vrtis, K. B., Zong, D., Chari, R., Callén, E., Pankajam, A. V., Zhen, G., Matos-Rodrigues, G. E., Yang, J., et al. (2024) · Science · doi:10.1126/science.ado3867 · Cited by 97
Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity
Bosse, K. R., Diskin, S. J., Cole, K. A., Wood, A., Schnepp, R. W., Norris, G. T., Nguyễn, L. B., Jagannathan, J., LaQuaglia, M. P., Winter, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3703 · Cited by 97
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
Mateo, J., Ong, M., Tan, D. S. P., Gonzalez, M. A., & de Bono, J. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.177 · Cited by 96
Deciphering the BRCA1 Tumor Suppressor Network
Jiang, Q., & Greenberg, R. A. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.r115.667931 · Cited by 96
Parallel High-Throughput RNA Interference Screens Identify PINK1 as a Potential Therapeutic Target for the Treatment of DNA Mismatch Repair–Deficient Cancers
Martin, S. A., Hewish, M., Sims, D., Lord, C. J., & Ashworth, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2836 · Cited by 96
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
Dougherty, B. A., Lai, Z., Hodgson, D., Orr, M. C. M., Hawryluk, M. J., Sun, J. X., Yelensky, R., Spencer, S., Robertson, J. D., Ho, T. W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17613 · Cited by 96

Authors: Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T.
Affiliations: University of Sheffield (GB)
Stockholm University (SE)
Newcastle University (GB)
Corresponding author: Helleday, Thomas
ORCID: Bryant, Helen E.
Thomas, Huw D.
Curtin, Nicola J.
Helleday, Thomas
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2005-04-14
Volume: 434
Issue: 7035
Pages: 913-917
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/nature03443
OpenAlex: W2009007206
Cited by: 5,198
References: 26
Citations by year: 2026: 213 · 2025: 256 · 2024: 286 · 2023: 355 · 2022: 355 · 2021: 396 · 2020: 388 · 2019: 282 · 2018: 290 · 2017: 273 · 2016: 265 · 2015: 230 · 2014: 243 · 2013: 223 · 2012: 213
FWCI: 56.59
Type: journal article
Language: en
Update notices: erratum (2007-05-17)
Open access: green
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Cancer Institute (F31CA260794)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Keywords: PARP inhibitors, BRCA2 deficiency, homologous recombination, synthetic lethality, breast cancer, PARP1, DNA repair, replication fork collapse, single-strand breaks, γH2AX foci, RAD51 foci, base excision repair
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Animals, Antineoplastic Agents, Benzodiazepines, DNA Damage, DNA Repair, DNA Replication, Mice, Nude, Neoplasms, Poly(ADP-ribose) Polymerases, Xenograft Model Antitumor Assays, Genes, BRCA2, BRCA2 Protein, Cell Line, Tumor, Mice, Azulenes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks